Wire · opportunities
NCS AUA 2026: Topline Results from BOND-003 Cohort P: A Multi-National, Single-Arm ...
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
The BOND-003 cohort P study reported topline results for intravesical cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy, targeting high-risk, papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). This therapy aims to provide a bladder-preserving treatment for patients with limited current options, addressing a significant unmet need in this specific patient group.
This Wire brief sits within Fusion42's coverage of Biotech, Drug Discovery and Medtech.
◆ ◆ The Wire takeaway
You need to position your biotech venture for new bladder cancer immunotherapies as research shows growing validation of oncolytic virus approaches in high-risk NMIBC. The unmet need in papillary-only cases opens a niche for differentiated, bladder-preserving therapies before radical surgery.
◆ Coverage
1 source · 16 Oct 2026
◆ Related on Wire
◆ Topics